284 related articles for article (PubMed ID: 23587606)
41. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
42. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
Wang LJ; Chen CK; Huang YS
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
[TBL] [Abstract][Full Text] [Related]
43. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
[TBL] [Abstract][Full Text] [Related]
44. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
45. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
Lage M; Hwang P
J Child Adolesc Psychopharmacol; 2004; 14(4):575-81. PubMed ID: 15662149
[TBL] [Abstract][Full Text] [Related]
46. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
[TBL] [Abstract][Full Text] [Related]
47. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
Leibson CL; Barbaresi WJ; Ransom J; Colligan RC; Kemner J; Weaver AL; Katusic SK
Ambul Pediatr; 2006; 6(1):45-53. PubMed ID: 16443183
[TBL] [Abstract][Full Text] [Related]
48. [Methylphenidate of retard forms in children and adolescents with ADHD - an overview].
Pelz R; Banaschewski T; Becker K
Klin Padiatr; 2008; 220(2):93-100. PubMed ID: 18157763
[TBL] [Abstract][Full Text] [Related]
49. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
50. Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder.
Wu SH; Wang K; Chen Y; Wang WQ; Wang F; Montgomery W; Treuer T
Asia Pac Psychiatry; 2017 Mar; 9(1):. PubMed ID: 26663807
[TBL] [Abstract][Full Text] [Related]
51. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study.
Wang LJ; Chen CK; Huang YS
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):501-8. PubMed ID: 26262904
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
53. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.
Pottegård A; Bjerregaard BK; Glintborg D; Kortegaard LS; Hallas J; Moreno SI
Eur J Clin Pharmacol; 2013 Mar; 69(3):589-98. PubMed ID: 22811260
[TBL] [Abstract][Full Text] [Related]
54. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
55. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
Yang P; Hsu HY; Chiou SS; Chao MC
Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
[TBL] [Abstract][Full Text] [Related]
56. [A pilot study of methylphenidate and parent training in the treatment of children with attention-deficit hiperactivity disorder].
Montiel Nava C; Peña JA; Espina Mariñes G; Ferrer-Hernandez ME; López-Rubio A; Puertas-Sánchez S; Cardozo-Durán JJ
Rev Neurol; 2002 Aug 1-15; 35(3):201-5. PubMed ID: 12235578
[TBL] [Abstract][Full Text] [Related]
57. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
[TBL] [Abstract][Full Text] [Related]
58. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Fredriksen M; Peleikis DE
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
[TBL] [Abstract][Full Text] [Related]
59. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
Schubert I; Köster I; Lehmkuhl G
Dtsch Arztebl Int; 2010 Sep; 107(36):615-21. PubMed ID: 20948775
[TBL] [Abstract][Full Text] [Related]
60. Treatment of attention-deficit/hyperactivity disorder.
Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
